 |
| March
25, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
 |
- Countable Labs: Brings Innovative,
Single-Molecule, Counting-Based PCR to
European Markets With CE Mark Clearance More
- Element Science: Named to Fast Company’s
Annual List of the World’s Most Innovative
Companies of 2026 More
- Encoded Therapeutics: FDA Alignment,
Initiation of Pivotal Study, and ASGCT
Presidential Symposium Presentation of ETX101
in Dravet Syndrome More
- HKeyBio: Launches HKEY-NHP-onChip 1.1:
World’s First NHP In Vitro Model for
Autoimmune and Allergic Diseases
More
- IASO Bio: Received Clearance From Japan's
PMDA to Initiate Clinical Trial for CAR-T
Therapy Equecabtagene Autoleucel in Second- or
Third-Line Multiple Myeloma More
- Manta Cares and Gilead Sciences:
Collaborate to Support Patients Navigating
Metastatic Lung and Breast Cancer More
More
- Maze Therapeutics: Positive Topline Data
From Phase 2 HORIZON Trial of MZE829
Demonstrating the First Clinical
Proof-of-Concept in Patients With Broad
APOL1-Mediated Kidney Disease More
More*
- Verana Health and Guardant Health: Partner
to Advance Precision Medicine With Real-World
Data More
- Viz.ai: Partners With Alnylam
Pharmaceuticals to Advance Earlier
Identification and Care Coordination in
Cardiac Amyloidosis More
More
More*
|
|
 |
|
Investment Banking Advisory to the
Life Science Industry |
|
Learn More
→ |
|
|
- Apogee Therapeutics: Pricing of $350 Million
Underwritten Public Offering More
- Arcus Biosciences: New Employment Inducement
Grants More
- BioAge Labs: Full Year 2025 Financial
Results and Business Updates From the Fourth
Quarter of 2025 More
- BioCardia: 2025 Business Highlights and
Financial Results More
- Biomea Fusion: Full Year 2025 Financial
Results and Corporate Highlights More
- Maze Therapeutics: Fourth Quarter and Full
Year 2025 Financial Results and Recent
Highlights More
- Merck: Will Acquire Terns
Pharmaceuticals, Inc., Expanding Its
Hematology Pipeline With TERN-701, a Novel
Candidate for Chronic Myeloid Leukemia (CML)
More
More
More*
More*
- More on Gilead, With Ouro Deal, Wagering
$1.7B on Bispecifics for Autoimmune Diseases More
More
More*
More*
- QT Imaging: 2025 Fourth Quarter and Full
Year Financial Results More
|
|
 |
| San
Francisco's most flexible contract
vivarium lab space: Start with a
few cages and grow. |
|
Learn More
→ |
|
|
|
- Immunotherapy for Solid Tumors Enhanced by
Metabolite-Sensing Receptors
More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- From Seed to Series C: What
Investors Look for Beyond the Science More
- Hiring Outlook: February Brings First YOY
Job Increase Since 2022 More
- ICYMI: CEO’s Perspective: Big Moves Come
with Big Responsibility More
- ICYMI: CEO’s Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- Idorsia Looks for Another CEO — Again;
Former Jazz Exec Makes a Comeback More*
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- 10 Companies Hiring in San Francisco and
South San Francisco More
- The Rise of Fractional Talent in Life
Sciences: What to Expect in 2026 More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: SFBay Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:SFBay,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
